NCT01723839: A trial that was reported late by Hackensack Meridian Health
This trial has reported, although it was 30 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT01723839 |
|---|---|
| Title | Phase II Clinical Protocol for the Treatment of Patients With Previously Untreated CLL With Four or Six Cycles of Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide Followed by Lenalidomide Consolidation/ Maintenance |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Feb. 22, 2012 |
| Completion date | June 8, 2021 |
| Required reporting date | June 8, 2022, midnight |
| Actual reporting date | July 8, 2022 |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | 30 |